Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts

Takayuki Yonezawa, Naomi Mase, Hiroaki Sasaki, Toshiaki Teruya, Shin Ichi Hasegawa, Byung Yoon Cha, Kazumi Yagasaki, Kiyotake Suenaga, Kazuo Nagai, Je Tae Woo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The mass and function of bones depend on the maintenance of a complicated balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. An inhibitor of osteoclast differentiation and/or function is expected to be useful for treatment of bone lytic diseases such as osteoporosis, rheumatoid arthritis, and tumor metastasis into bone. Biselyngbyaside is a recently isolated macrolide compound from marine cyanobacteria Lyngbya sp. that shows wide-spectrum cytotoxicity toward human tumor cell lines. In this study, we investigated the effects of biselyngbyaside on osteoclast differentiation and function. Biselyngbyaside inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in mouse monocytic RAW264 cells and primary bone marrow-derived macrophages at a low concentration. Similarly, biselyngbyaside suppressed osteoblastic cell-mediated osteoclast differentiation in cocultures. In the RANKL-induced signaling pathway, biselyngbyaside inhibited the expression of c-Fos and NFATc1, which are important transcription factors in osteoclast differentiation. In mature osteoclasts, biselyngbyaside decreased resorption-pit formation. Biselyngbyaside also induced apoptosis accompanied by the induction of caspase-3 activation and nuclear condensation, and these effects were negated by the pancaspase inhibitor z-VAD-FMK. Taken together, the present findings indicate that biselyngbyaside suppresses bone resorption via inhibition of osteoclastogenesis and induction of apoptosis. Thus, biselyngbyaside may be useful for the prevention of bone lytic diseases.

Original languageEnglish
Pages (from-to)440-448
Number of pages9
JournalJournal of Cellular Biochemistry
Volume113
Issue number2
DOIs
Publication statusPublished - 2012 Feb

Fingerprint

Cyanobacteria
Osteoclasts
Osteogenesis
Bone
Apoptosis
Bone Diseases
Bone Resorption
Tumors
biselyngbyaside
Bone and Bones
Macrophages
Osteoblasts
Macrolides
Cytotoxicity
Cytoplasmic and Nuclear Receptors
Coculture Techniques
Tumor Cell Line
Caspase 3
Osteoporosis
Condensation

Keywords

  • Apoptosis
  • Biselyngbyaside
  • Bone resorption
  • Differentiation
  • Macrolide
  • Osteoclast

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts. / Yonezawa, Takayuki; Mase, Naomi; Sasaki, Hiroaki; Teruya, Toshiaki; Hasegawa, Shin Ichi; Cha, Byung Yoon; Yagasaki, Kazumi; Suenaga, Kiyotake; Nagai, Kazuo; Woo, Je Tae.

In: Journal of Cellular Biochemistry, Vol. 113, No. 2, 02.2012, p. 440-448.

Research output: Contribution to journalArticle

Yonezawa, T, Mase, N, Sasaki, H, Teruya, T, Hasegawa, SI, Cha, BY, Yagasaki, K, Suenaga, K, Nagai, K & Woo, JT 2012, 'Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts', Journal of Cellular Biochemistry, vol. 113, no. 2, pp. 440-448. https://doi.org/10.1002/jcb.23213
Yonezawa, Takayuki ; Mase, Naomi ; Sasaki, Hiroaki ; Teruya, Toshiaki ; Hasegawa, Shin Ichi ; Cha, Byung Yoon ; Yagasaki, Kazumi ; Suenaga, Kiyotake ; Nagai, Kazuo ; Woo, Je Tae. / Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts. In: Journal of Cellular Biochemistry. 2012 ; Vol. 113, No. 2. pp. 440-448.
@article{edf294a2449740879103a0cf38e54b84,
title = "Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts",
abstract = "The mass and function of bones depend on the maintenance of a complicated balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. An inhibitor of osteoclast differentiation and/or function is expected to be useful for treatment of bone lytic diseases such as osteoporosis, rheumatoid arthritis, and tumor metastasis into bone. Biselyngbyaside is a recently isolated macrolide compound from marine cyanobacteria Lyngbya sp. that shows wide-spectrum cytotoxicity toward human tumor cell lines. In this study, we investigated the effects of biselyngbyaside on osteoclast differentiation and function. Biselyngbyaside inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in mouse monocytic RAW264 cells and primary bone marrow-derived macrophages at a low concentration. Similarly, biselyngbyaside suppressed osteoblastic cell-mediated osteoclast differentiation in cocultures. In the RANKL-induced signaling pathway, biselyngbyaside inhibited the expression of c-Fos and NFATc1, which are important transcription factors in osteoclast differentiation. In mature osteoclasts, biselyngbyaside decreased resorption-pit formation. Biselyngbyaside also induced apoptosis accompanied by the induction of caspase-3 activation and nuclear condensation, and these effects were negated by the pancaspase inhibitor z-VAD-FMK. Taken together, the present findings indicate that biselyngbyaside suppresses bone resorption via inhibition of osteoclastogenesis and induction of apoptosis. Thus, biselyngbyaside may be useful for the prevention of bone lytic diseases.",
keywords = "Apoptosis, Biselyngbyaside, Bone resorption, Differentiation, Macrolide, Osteoclast",
author = "Takayuki Yonezawa and Naomi Mase and Hiroaki Sasaki and Toshiaki Teruya and Hasegawa, {Shin Ichi} and Cha, {Byung Yoon} and Kazumi Yagasaki and Kiyotake Suenaga and Kazuo Nagai and Woo, {Je Tae}",
year = "2012",
month = "2",
doi = "10.1002/jcb.23213",
language = "English",
volume = "113",
pages = "440--448",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts

AU - Yonezawa, Takayuki

AU - Mase, Naomi

AU - Sasaki, Hiroaki

AU - Teruya, Toshiaki

AU - Hasegawa, Shin Ichi

AU - Cha, Byung Yoon

AU - Yagasaki, Kazumi

AU - Suenaga, Kiyotake

AU - Nagai, Kazuo

AU - Woo, Je Tae

PY - 2012/2

Y1 - 2012/2

N2 - The mass and function of bones depend on the maintenance of a complicated balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. An inhibitor of osteoclast differentiation and/or function is expected to be useful for treatment of bone lytic diseases such as osteoporosis, rheumatoid arthritis, and tumor metastasis into bone. Biselyngbyaside is a recently isolated macrolide compound from marine cyanobacteria Lyngbya sp. that shows wide-spectrum cytotoxicity toward human tumor cell lines. In this study, we investigated the effects of biselyngbyaside on osteoclast differentiation and function. Biselyngbyaside inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in mouse monocytic RAW264 cells and primary bone marrow-derived macrophages at a low concentration. Similarly, biselyngbyaside suppressed osteoblastic cell-mediated osteoclast differentiation in cocultures. In the RANKL-induced signaling pathway, biselyngbyaside inhibited the expression of c-Fos and NFATc1, which are important transcription factors in osteoclast differentiation. In mature osteoclasts, biselyngbyaside decreased resorption-pit formation. Biselyngbyaside also induced apoptosis accompanied by the induction of caspase-3 activation and nuclear condensation, and these effects were negated by the pancaspase inhibitor z-VAD-FMK. Taken together, the present findings indicate that biselyngbyaside suppresses bone resorption via inhibition of osteoclastogenesis and induction of apoptosis. Thus, biselyngbyaside may be useful for the prevention of bone lytic diseases.

AB - The mass and function of bones depend on the maintenance of a complicated balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. An inhibitor of osteoclast differentiation and/or function is expected to be useful for treatment of bone lytic diseases such as osteoporosis, rheumatoid arthritis, and tumor metastasis into bone. Biselyngbyaside is a recently isolated macrolide compound from marine cyanobacteria Lyngbya sp. that shows wide-spectrum cytotoxicity toward human tumor cell lines. In this study, we investigated the effects of biselyngbyaside on osteoclast differentiation and function. Biselyngbyaside inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in mouse monocytic RAW264 cells and primary bone marrow-derived macrophages at a low concentration. Similarly, biselyngbyaside suppressed osteoblastic cell-mediated osteoclast differentiation in cocultures. In the RANKL-induced signaling pathway, biselyngbyaside inhibited the expression of c-Fos and NFATc1, which are important transcription factors in osteoclast differentiation. In mature osteoclasts, biselyngbyaside decreased resorption-pit formation. Biselyngbyaside also induced apoptosis accompanied by the induction of caspase-3 activation and nuclear condensation, and these effects were negated by the pancaspase inhibitor z-VAD-FMK. Taken together, the present findings indicate that biselyngbyaside suppresses bone resorption via inhibition of osteoclastogenesis and induction of apoptosis. Thus, biselyngbyaside may be useful for the prevention of bone lytic diseases.

KW - Apoptosis

KW - Biselyngbyaside

KW - Bone resorption

KW - Differentiation

KW - Macrolide

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=84855551980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855551980&partnerID=8YFLogxK

U2 - 10.1002/jcb.23213

DO - 10.1002/jcb.23213

M3 - Article

VL - 113

SP - 440

EP - 448

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -